These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23604106)

  • 21. Novel tools to assist neoepitope targeting in personalized cancer immunotherapy.
    Saini SK; Rekers N; Hadrup SR
    Ann Oncol; 2017 Dec; 28(suppl_12):xii3-xii10. PubMed ID: 29092006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CANCER IMMUNOLOGY. The "cancer immunogram".
    Blank CU; Haanen JB; Ribas A; Schumacher TN
    Science; 2016 May; 352(6286):658-60. PubMed ID: 27151852
    [No Abstract]   [Full Text] [Related]  

  • 23. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
    Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
    J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
    Blass E; Ott PA
    Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms regulating T-cell infiltration and activity in solid tumors.
    Lanitis E; Dangaj D; Irving M; Coukos G
    Ann Oncol; 2017 Dec; 28(suppl_12):xii18-xii32. PubMed ID: 29045511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
    Ioannides CG; Whiteside TL
    Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
    Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
    Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and future molecular profiling of cancer by next-generation sequencing.
    Shibata T
    Jpn J Clin Oncol; 2015 Oct; 45(10):895-9. PubMed ID: 26292697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy.
    Aversa I; Malanga D; Fiume G; Palmieri C
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation sequencing in the clinic: promises and challenges.
    Xuan J; Yu Y; Qing T; Guo L; Shi L
    Cancer Lett; 2013 Nov; 340(2):284-95. PubMed ID: 23174106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
    Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoinformatics and epitope prediction in the age of genomic medicine.
    Backert L; Kohlbacher O
    Genome Med; 2015 Nov; 7():119. PubMed ID: 26589500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Converging on a Cure: The Roads to Predictive Immunotherapy.
    Stein-O'Brien GL; Le DT; Jaffee EM; Fertig EJ; Zaidi N
    Cancer Discov; 2023 May; 13(5):1053-1057. PubMed ID: 37067199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.
    Diken M; Vormehr M; Grunwitz C; Kreiter S; Türeci Ö; Sahin U
    Methods Mol Biol; 2017; 1499():223-236. PubMed ID: 27987153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer.
    Magalhaes I; Carvalho-Queiroz C; Hartana CA; Kaiser A; Lukic A; Mints M; Nilsson O; Grönlund H; Mattsson J; Berglund S
    Expert Opin Biol Ther; 2019 Aug; 19(8):811-827. PubMed ID: 30986360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.